JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Neutrophilic eccrine hidradenitis: report of two cases.

Journal of Dermatology 1995 Februrary
BACKGROUND: Neutrophilic eccrine hidradenitis (NEH) is an uncommon, self-limited dermatosis usually attributed to anti-cancer chemotherapy. It is characterized histologically by necrosis of the eccrine gland and neutrophilic infiltrate.

OBSERVATIONS: We saw NEH in a 5-year-old boy with acute lymphoblastic leukemia and a 4-year-old girl with acute monocytic leukemia. NEH developed after the anti-leukemic chemotherapy including high dose cytarabine. The eruption was composed of vesicles, papules, and plaques.

CONCLUSIONS: Histological findings were compatible with those described in the literature. NEH in our two patients could be attributed to high doses of cytarabine.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app